首頁 > 市場調查報告書 > 製藥

生物製劑分子標靶治療學

市場調查報告書

商品編碼

1783853

癌症抗體藥物複合體的全球市場:市場機會，專利，價格，已核准藥物銷售和臨床試驗趨勢(2031年)

Global Cancer Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales & Clinical Trials Insight 2031

出版日期: 2025年08月01日 | 出版商:

KuicK Research | 英文 1300 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

癌症抗體藥物複合體的全球市場:市場機會，專利，價格，已核准藥物銷售和臨床試驗趨勢(2031年)報告結果及亮點

全球癌症抗體-藥物偶聯物市場機會：到2031年將超過700億美元
全球及各地區市場規模洞察（年度及季度）：2020年至2025年上半年
全球癌症抗體-藥物偶聯物市場預測：2026年至2031年
已核准癌症抗體-藥物偶聯物數量：超過20種抗體-藥物偶聯物
已核准癌症抗體-藥物偶聯物的收入洞察： 2020-2025
已核准的癌症抗體-藥物偶聯物的專利、劑量和價格分析
臨床試驗中的癌症抗體-藥物偶聯物：超過800種藥物
公司、國家、適應症和階段劃分的癌症抗體-藥物偶聯物臨床試驗洞察

對癌症抗體-藥物偶聯物的需求及本報告的意義

化療和放療等傳統治療方法通常毒性大，且缺乏對正常組織的特異性，導致患者治療選擇有限，有時甚至病情嚴重。因此，對有效且強效的癌症標靶療法的需求從未如此強烈。從這個意義上講，癌症抗體藥物偶聯物 (ADC) 代表了癌症治療的新前沿，它將單株抗體的選擇性與化療藥物的療效相結合，選擇性地殺死癌細胞，同時最大限度地減少對正常組織的損害。全球已有 20 多種抗體-藥物偶聯物獲批，其治療成功正在徹底改變癌症治療。

本報告分析了不斷擴張的癌症抗體-藥物偶聯物市場及其在現代腫瘤學中日益重要的作用。報告中還記錄了最新的科學進展，監測了臨床研發管線趨勢，並重點介紹了未來的商業和臨床前景，為投資者在這個高風險、高回報的治療領域提供關鍵見解。

已核准癌症抗體-藥物偶聯物的市場機會、銷售、定價和劑量洞察

本報告詳細概述了20種已核准癌症抗體-藥物偶聯物在2020年至2025年上半年的定價、建議劑量和銷售數據。報告包含全球和區域洞察，以及季度銷售業績分析。報告概述了全球範圍內癌症抗體-藥物偶聯物市場在此期間的總市值，並重點介紹了各個藥物對整體市場的貢獻。

報告中包含的臨床試驗洞察

臨床試驗透過提供抗體-藥物偶聯物在各種癌症（包括實體癌和血液癌）中的治療價值洞察，為抗體-藥物偶聯物的開發提供支持。目前，超過800種癌症抗體-藥物偶聯物正在臨床試驗中或已獲批，用於評估其在各種癌症適應症中的安全性和有效性，或擴大可治療的患者群體。例如，阿斯特捷利康和第一三共的TROPION試驗系列目前正在評估達泊單抗（dapotamab deruxtecan）在其核准用途之外的各種實體瘤中的應用。 Genmab的RAINFOL試驗也正在研究利那巴布（linatabat cestane）在各種實體瘤中的潛力。這些試驗對於展示抗體-藥物偶聯物如何滿足大量未滿足的醫療需求至關重要。

本報告詳細概述了主要癌症抗體-藥物偶聯物的臨床試驗，以及抗體-藥物偶聯物正在測試的適應症、試驗申辦方、地區背景和試驗階段的數據，旨在幫助利益相關者準確了解當前的開發狀態。這些見解對於需要隨時了解產品線發展動能和治療潛力的商業決策者和學術研究人員來說，是一份寶貴的備忘錄。

技術平台、合作與協議

開發用於癌症治療的抗體-藥物偶聯物需要能夠促進將細胞毒性有效載荷靶向遞送至癌細胞的技術平台。例如，第一三共的 DXd 平台透過提高穩定性和控制有效載荷釋放，推動了 Enhertu 和 Datroway 等抗體-藥物偶聯物的成功。

策略夥伴關係、收購對象和授權協議也同樣重要，它們可以加快開發進度，增加獲得新標靶的機會，並促進全球市場准入。這些協議不僅推動了癌症抗體-藥物偶聯物的創新，也確保了在競爭日益激烈的腫瘤學領域中獲得更高的臨床療效和商業成功。

參與癌症抗體藥物偶聯物研發的主要公司

目前，一些知名製藥公司正處於癌症抗體-藥物偶聯物研發的前沿。例如，輝瑞公司收購了抗體藥物偶聯物技術領域的領導者Siegen，利用其先進的平台和專業知識，增強了其癌症治療產品組合。阿斯特捷利康公司也正在加強其癌症抗體-藥物偶聯物產品線，推出針對多種癌症（包括卵巢癌和乳癌）的候選化合物。像美雅珂這樣的新興生物技術公司，憑藉其前景光明的抗體-藥物偶聯物MRG003，也正在利用新技術和給藥機制來提高療效並減少副作用，從而引起轟動。

本報告全面分析了推動癌症抗體-藥物偶聯物創新的關鍵公司，涵蓋傳統製藥公司、新興生物技術公司以及新興技術提供者。報告重點介紹了每家公司的策略重點、產品線開發以及在推動癌症標靶療法未來發展方面所發揮的作用。

本報告重點介紹了癌症抗體-藥物偶聯物領域的未來發展方向。

在持續的技術改進、新型有效載荷和改進的連接體系統的推動下，癌症抗體-藥物偶聯物的未來前景光明。隨著新型抗體-藥物偶聯物（例如用於治療非小細胞肺癌的Emrelis和用於治療HER2陽性乳癌的曲妥珠單抗-瑞澤替康）的持續獲批，其在腫瘤學領域的潛力日益增長。除了已核准的療法外，下一代抗體-藥物偶聯物（例如雙特異性和免疫增強型抗體-藥物偶聯物）也有望徹底改變癌症治療。這些療法有望解決腫瘤異質性問題並改善預後。

本報告透過分析科學和監管趨勢以及治療進展，探討了癌症抗體-藥物偶聯物行業的未來發展方向，並提供了未來展望。報告強調，需要製定以生物標記為導向的策略、個人化給藥和轉化試驗設計，以最大限度地發揮抗體-藥物偶聯物在實體癌症和血液癌中的臨床潛力。

Global Cancer Antibody Drug Conjugates Market Opportunity: > USD 70 Billion By 2031
Global & Regional Market Size Insight (Yearly & Quarterly): 2020 Till H1'2025
Global Cancer Antibody Drug Conjugates Market Forecast: 2026 Till 2031
Number Of Approved Cancer Antibody Drug Conjugates: > 20 Antibody Drug Conjugates
Approved Cancer Antibody Drug Conjugates Sales Insight : 2020 Till 2025
Approved Cancer Antibody Drug Conjugates Patent, Dosage & Price Analysis
Cancer Antibody Drug Conjugates In Clinical Trials: > 800 Drugs
Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication and Phase

Need For Cancer Antibody Drug Conjugates & Why This Report?

Traditional treatments such as chemotherapy and radiation are frequently associated with high toxicity and fail to provide the specificity that would allow for sparing of normal tissue, so that patients are left with few and sometimes severe treatment options. Consequently, the demand for effective powerful and targeted cancer therapies has never been greater. In this sense, Cancer Antibody Drug Conjugates (ADCs) represent a new frontier in cancer therapy, marrying the selectivity of monoclonal antibodies with the potency of chemotherapy drugs to selectively kill cancer cells while reducing harm to normal tissue. With over 20 antibody drug conjugates approved globally, their therapeutic success is revolutionizing cancer treatment.

This report provides an analysis of the expanding cancer antibody drug conjugates market and its increasingly prominent role in modern oncology. It also records the most recent scientific advances, monitors developments through clinical pipelines, and identifies future commercial and clinical prospects, thus providing key insight for investors to navigate this high-risk, high-reward therapeutic area.

Market Opportunity, Approved Cancer Antibody Drug Conjugates Sales, Pricing, & Dosing Insight

This report provides a detailed overview of pricing, recommended dosing, and sales data for the 20 approved cancer antibody drug conjugates from 2020 to the first half of 2025. It includes both global and regional insights, along with a quarterly breakdown of sales performance. At the global level, the report outlines the total market value of the cancer antibody drug conjugates market over this period and highlights how each individual drug contributes to overall market figures.

Clinical Trials Insight Included In Report

Clinical trials are at the backbone of antibody drug conjugates development, offering insights into their utility in the treatment of a number of cancers, such as solid tumors and blood cancers. Currently, more than 800 cancer antibody drug conjugates both under investigation and approved, are being tested in clinical trials, aimed at evaluating their safety and efficacy in different cancer indications or broadening their treatable patient population. For instance, AstraZeneca and Daiichi Sankyo's TROPION trial series is currently assessing Datopotamab deruxtecan in a variety of solid tumors outside its approved uses. Genmab's RAINFOL trials are also examining the potential of Rinatabart Sesutecan in various solid tumors. These trials are critical in demonstrating how antibody drug conjugates can address high, unmet medical needs

The report contains an in-depth overview of key cancer antibody drug conjugates clinical trials, along with data on indications being tested by antibody drug conjugates, the trial sponsors, geographic regions and trial phases, providing stakeholders with an accurate picture of the development landscape at present. These observations are a valuable reminder for both commercial decision-makers and academic researchers who need to stay informed of pipeline momentum and therapeutic potential.

Technology Platforms, Collaborations & Agreements

Technology platforms are crucial to the development of antibody drug conjugates for cancer treatment, facilitating targeted delivery of cytotoxic payload to cancer cells. To illustrate this, Daiichi Sankyo's DXd platform has driven the success of antibody drug conjugates such as Enhertu and Datroway, with improved stability and controlled payload release.

Equally important are strategic partnerships, candidate acquisitions and licensing deals, that expedite development timelines, increase access to new targets, and fuel global market reach. These agreements are necessary not only to promote cancer antibody drug conjugates innovation but also to guarantee greater clinical impact and commercial success in an increasingly competitive oncology landscape.

Key Companies Involved in R&D of Cancer Antibody Drug Conjugates

Several prominent drug makers are now active at the forefront of cancer antibody drug conjugates research and development. For instance, Pfizer has enhanced its cancer treatment portfolio by acquiring Seagen, a leader in antibody drug conjugates technology, gaining access to its advanced platform and expertise in the field. AstraZeneca has also strengthened its cancer antibody drug conjugates pipeline, with candidates aiming at a range of cancers, such as ovarian and breast cancers. Emerging biotech firms like Miracogen, with its promising antibody drug conjugates MRG003, are also making waves, centering on new technologies and delivery mechanisms to improve efficacy and reduce side effects.

This report presents a comprehensive analysis of the companies leading cancer antibody drug conjugates innovation, ranging from the traditional pharmaceutical powerhouses to the new biotech upstarts, as well as the occasional technology providers. It identifies each company's strategic emphasis, pipeline development, and role in driving the future of targeted cancer treatment.

Report Highlighting Future Direction of Cancer Antibody Drug Conjugates Segment

The future of cancer antibody drug conjugates is promising, with ongoing technology improvement, new payloads, and improved linker systems. As new antibody drug conjugates continue receiving approval, like Emrelis for non-small cell lung cancer and Trastuzumab rezetecan for HER2-positive breast cancer, their potential in oncology are increasing. Besides those therapies already approved, next-generation antibody drug conjugates, including bispecific antibody drug conjugates and immune-enhancing antibody drug conjugates, are also anticipated to revolutionize cancer therapy. These treatments hold the promise of addressing tumor heterogeneity and enhancing outcome.

Providing a vision of the future, this report examines the future direction of the cancer antibody drug conjugates industry, with analysis of scientific trends, regulatory trends, and therapeutic advances. It highlights the need for biomarker-driven strategies, individualized dosing, and translational trial design in order to realize the maximum clinical potential of antibody drug conjugates in both solid tumors and hematological cancers.

1. RESEARCH METHODOLOGY

2. Introduction To Antibody Drug Conjugates

2.1 Overview
2.2 Mechanism of Antibody Drug Conjugates

3. Antibody Drug Conjugates As Cancer Targeted Therapy

3.1 Applications of Antibody Drug Conjugates in Cancer
3.2 Advantages of Antibody Drug Conjugates
3.3 Comparison of Antibody Drug Conjugates With Traditional Therapies

4. Generations of Antibody Drug Conjugates

4.1 Antibody Drug Conjugates - Evolution
4.2 Next Generation Antibody Drug Conjugates Prospects

5. Commercially Approved Antibody Drug Conjugates By Brand Name, Company & Indication

6. Global Cancer Antibody Drug Conjugates Market Outlook

6.1 Current Market Scenario
6.2 Future Growth Avenues

7. Global Cancer Antibody Drug Conjugates Research & Market Trends by Region

7.1 US
7.2 China
7.3 Europe
7.4 South Korea
7.5 Australia
7.6 UK
7.7 Canada
7.8 Japan
7.9 India
7.10 Latin America

8. Global Cancer Antibody Drug Conjugates Market Trends & Development By Indications

8.1 Lung Cancer
8.2 Breast cancer
8.3 Leukemia
8.4 Ovarian Cancer
8.5 Gastrointestinal Cancers
8.6 Lymphoma
8.7 Urothelial Carcinoma
8.8 Cervical Cancer
8.9 Head & Neck Cancer
8.10 Brain Cancer
8.11 Prostate cancer
8.12 Pancreatic Cancer
8.13 Skin cancer
8.14 Esophageal cancer

9. Cancer Antibody Drug Conjugates Development Platforms By Company

10. Approved Cancer Antibody Drug Conjugates - Patent, Dosage & Price Analysis

This Chapter Gives Comprehensive Insight On Patent, Dosage & Price Analysis For 20 Approved Cancer Antibody Drug Conjugates. We Have Mentioned Few Drug Conjugates Names For Reference, Detailed Insight Included In Sample & Report

10.1 Mylotarg
- 10.1.1 Overview, Availability & Patent Insight
- 10.1.2 Pricing & Dosage Insight
10.2 Adcetris
- 10.2.1 Overview, Availability & Patent Insight
- 10.2.2 Pricing & Dosage Insight
10.3 Kadcyla
- 10.3.1 Overview, Availability & Patent Insight
- 10.3.2 Pricing & Dosage Insight
10.4 Besponsa
- 10.4.1 Overview & Availability Insight
- 10.4.2 Pricing & Dosage Insight
10.5 Lumoxiti (Market Withdrawal In 2023)
- 10.5.1 Overview, Availability & Patent Insight
- 10.5.2 Pricing & Dosage Insight
10.6 Polivy
- 10.6.1 Overview, Availability & Patent Insight
- 10.6.2 Pricing & Dosage Insight

11. Approved Cancer Antibody Drug Conjugates - Sales Insights 2020 - 2025

11.1 Adcetris
11.2 Padcev
11.3 Tivdak
11.4 Polivy
11.5 Kadcyla
11.6 Besponsa
11.7 Enhertu
11.8 Trodelvy
11.9 Zynlonta
11.10 Elahere
11.11 Blenrep
11.12 Datroway

12. Global Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase

12.1 Research
12.2 Preclinical
12.3 Phase I
12.4 Phase I/II
12.5 Phase II
12.6 Phase II/III
12.7 Phase III
12.8 Preregistration
12.9 Registration

13. Marketed Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase

14. Cancer Antibody Drug Conjugates Combination Therapies

15. Global Cancer Antibody Drug Conjugates Market Overview

15.1 Key Market Growth Drivers
15.2 Challenges For Market Growth

16. Competitive Landscape

16.1 ADC Therapeutics
16.2 Affinity Biopharma
16.3 AstraZeneca
16.4 Biocytogen
16.5 Biokin
16.6 Bristol Myers Squibb
16.7 Daiichi Sankyo
16.8 Duality Biologics
16.9 Eli Lilly
16.10 Immunogen
16.11 Innovent Biologics
16.12 LigaChem Biosciences
16.13 Merck
16.14 Pfizer
16.15 Synaffix

簡介目錄圖表

List of Figures

Figure 2-1: Antibody Drug Conjugates - General Working Mechanism
Figure 3-1: Advantages of Antibody Drug Conjugates
Figure 4-1: Antibody-Drug Conjugates - Approval by Generation
Figure 4-2: Cancer Antibody Drug Conjugates - Opportunities for Next-Generation Development
Figure 6-1: Global - Cancer Antibody Drug Conjugates Market (US$ Million), 2020-2025
Figure 6-2: Global -Cancer Antibody Drug Conjugate Sales by Drug (US$ Million), H1'2025
Figure 6-3: Global - Cancer Antibody Drug Conjugate Sales by Drug (US$ Million), 2024
Figure 6-4: Global - Cancer Antibody Drug Conjugate Market Share by Drugs (%), 2024
Figure 6-5: Global - Cancer Antibody Drug Conjugate Market (US$ Million), Q1-Q4'2024
Figure 6-6: Global - Cancer Antibody Drug Conjugate Market by Drug (US$ Million), 2023
Figure 6-7: Global - Cancer Antibody Drug Conjugate Market Share by Drugs (%), 2023
Figure 6-8: Global - Cancer Antibody Drug Conjugate Market Forecast (US$ Billion), 2025 - 2031
Figure 7-1: Daiichi Sankyo DXd ADC Technology - Clinical Candidates
Figure 7-2: India - Branded v/s Biosimilar Trastuzumab Emtansine Price by Supply (US$), August'2025
Figure 8-1: REFRaME-L1 Phase 2 (NCT06555263) Study - Initiation & Completion Year
Figure 8-2: IDeate-Lung02 Phase 3 (NCT06203210) Study - Initiation & Completion Year
Figure 8-3: SGNB6A-001 Phase 1 (NCT04389632) Study - Initiation & Completion Year
Figure 8-4: SGNB6A-002 Phase 3 (NCT06012435) Study - Initiation & Completion Year
Figure 8-5: MK-2870-004 Phase 3 (NCT06074588) Study - Initiation & Completion Year
Figure 8-6: SHR-4849-101 Phase 1 (NCT06443489) Study - Initiation & Completion Year
Figure 8-7: D926QC00001 Phase 3 (NCT06112379) Study - Initiation & Completion Year
Figure 8-8: TQB2102-III-01 Phase 3 (NCT06561607) Study - Initiation & Completion Year
Figure 8-9: IZABRIGHT-Breast01 Phase 2/3 (NCT06926868) Study - Initiation & Completion Year
Figure 8-10: STARt-002 Phase 1/2 (NCT06827613) Study - Initiation & Completion Year
Figure 8-11: CA235-0001 Phase 1 (NCT06419634) Study - Initiation & Completion Year
Figure 8-12: VNC-943-101 Phase 1 (NCT06034275) Study - Initiation & Completion Year
Figure 8-13: RAINFOL-02 Phase 3 (NCT06619236) Study - Initiation & Completion Year
Figure 8-14: RAINFOL-01 Phase 1/2 (NCT05579366) Study - Initiation & Completion Year
Figure 8-15: DS6000-109 Phase 2/3 (NCT06161025) Study - Initiation & Completion Year
Figure 8-16: FONTANA Phase 1/2 (NCT05797168) Study - Initiation & Completion Year
Figure 8-17: LOXO-FRA-24001 Phase 1 (NCT06400472) Study - Initiation & Completion Year
Figure 8-18: M24-427 Phase 1 (NCT06084481) Study - Initiation & Completion Year
Figure 8-19: CUSP06-1001 Phase 1 (NCT06234423) Study - Initiation & Completion Year
Figure 8-20: TROPION-PanTumor03 Phase 2 (NCT05489211) Study - Initiation & Completion Year
Figure 8-21: IKS014-01 Phase 1 (NCT05872295) Study - Initiation & Completion Year
Figure 8-22: D9800C00001 Phase 2 (NCT06219941) Study - Initiation & Completion Year
Figure 8-23: PROCEADE-PanTumor Phase 1/2 (NCT06710132) Study - Initiation & Completion Year
Figure 8-24: CIBI343A101 Phase 1 (NCT05458219) Study - Initiation & Completion Year
Figure 8-25: CTMX-2051-101 Phase 2 (NCT06265688) Study - Initiation & Completion Year
Figure 8-26: M21-404 Phase 1 (NCT05029882) Study - Initiation & Completion Year
Figure 8-27: EBC-129-01 Phase 1 (NCT05701527) Study - Initiation & Completion Year
Figure 8-28: ADRX-0405-001 Phase 1 (NCT06710379) Study - Initiation & Completion Year
Figure 8-29: Polatuzumab Vedotin Phase 2 (NCT05410418) Study - Initiation & Completion Year
Figure 8-30: RG1122400 Phase 2 (NCT05453396) Study - Initiation & Completion Year
Figure 8-31: Blenrep Phase 2 (NCT04676360) Study - Initiation & Completion Year
Figure 8-32: Blenrep Phase 2 (NCT04676360) Study - Initiation & Completion Year
Figure 8-33: waveLINE-003 Phase 2/3 (NCT05139017) Study - Initiation & Completion Year
Figure 8-34: waveLINE-010 Phase 3 (NCT06717347) Study - Initiation & Completion Year
Figure 8-35: waveLINE-007 Phase 2 (NCT05406401) Study - Initiation & Completion Year
Figure 8-36: waveLINE-006 Phase 2 (NCT05458297) Study - Initiation & Completion Year
Figure 8-37: SUNMO Phase 3 (NCT05171647) Study - Initiation & Completion Year
Figure 8-38: NCI-2023-00999 Phase 2 (NCT05775471) Study - Initiation & Completion Year
Figure 8-39: RG1122399 Phase 2 (NCT05581589) Study - Initiation & Completion Year
Figure 8-40: BL-B01D1 Phase 2 (NCT05785039) Study - Initiation & Completion Year
Figure 8-41: 9MW2821-2023-CP301 Phase 3 (NCT06196736) Study - Initiation & Completion Year
Figure 8-42: IDE397-001 Phase 1/2 (NCT04794699) Study - Initiation & Completion Year
Figure 8-43: ADCE-T02-01 Phase 1 (NCT06597721) Study - Initiation & Completion Year
Figure 8-44: 2000023639 Phase 2 (NCT05838521) Study - Initiation & Completion Year
Figure 8-45: DESTINY-PanTumor02 Phase 2 (NCT04482309) Study - Initiation & Completion Year
Figure 8-46: 9MW2821-2021-CP102 Phase 1/2 (NCT05216965) Study - Initiation & Completion Year
Figure 8-47: ADRX-0706-001 Phase 1 (NCT06036121) Study - Initiation & Completion Year
Figure 8-48: CRB-701-01 Phase 1/2 (NCT06265727) Study - Initiation & Completion Year
Figure 8-49: SGNDV-005 Phase 2 (NCT06003231) Study - Initiation & Completion Year
Figure 8-50: EV-202 Phase 2 (NCT04225117) Study - Initiation & Completion Year
Figure 8-51: CRB-701-01 Phase 1/2 (NCT06265727) Study - Initiation & Completion Year
Figure 8-52: SGNPDL1V-001 Phase 1 (NCT05208762) Study - Initiation & Completion Year
Figure 8-53: DB-1311-O-1001 Phase 1/2 (NCT05914116) Study - Initiation & Completion Year
Figure 8-54: IRB-43179 Phase 1/2 (NCT03510208) Study - Initiation & Completion Year
Figure 8-55: MEDOPP575 Phase 2 (NCT05865990) Study - Initiation & Completion Year
Figure 8-56: UW18043 Phase 2 (NCT03725761) Study - Initiation & Completion Year
Figure 8-57: ARTEMIS-003 Phase 2 (NCT06001255) Study - Initiation & Completion Year
Figure 8-58: NCI-2021-08857 Phase 1b/2 (NCT05011188) Study - Initiation & Completion Year
Figure 8-59: IDeate-Prostate01 Phase 3 (NCT06925737) Study - Initiation & Completion Year
Figure 8-60: IDeate-PanTumor01 Phase 1/2 (NCT04145622) Study - Initiation & Completion Year
Figure 8-61: Pancreatic Ductal Adenocarcinoma - Prevalence Compared to Other Pancreatic Cancer Types
Figure 8-62: TORL2307ADC-001 Phase 1 (NCT05156866) Study - Initiation & Completion Year
Figure 8-63: EBC-129-01 Phase 1 (NCT05701527) Study - Initiation & Completion Year
Figure 8-64: XNW27011-I/II-01 Phase 1/2 (NCT06792435) Study - Initiation & Completion Year
Figure 8-65: BA3021-001 Phase 1/2 (NCT03504488) Study - Initiation & Completion Year
Figure 8-66: CP-MGC018-02 Phase 1 (NCT05293496) Study - Initiation & Completion Year
Figure 8-67: AMT-253-02 Phase 1/2 (NCT06209580) Study - Initiation & Completion Year
Figure 8-68: SGN35-033 Phase 2 (NCT04609566) Study - Initiation & Completion Year
Figure 8-69: BrUOG 413 Phase 2 (NCT05480384) Study - Initiation & Completion Year
Figure 8-70: SYSA1501-010 Phase 1/2 (NCT06577376) Study - Initiation & Completion Year
Figure 8-71: 202401158MIFD Phase 2 (NCT06329869) Study - Initiation & Completion Year
Figure 8-72: HS-20093-203 Phase 2 (NCT06112704) Study - Initiation & Completion Year
Figure 8-73: IDeate-Esophageal01 Phase 2 (NCT06644781) Study - Initiation & Completion Year
Figure 8-74: BL-B01D1-103 Phase 1 (NCT05262491) Study - Initiation & Completion Year
Figure 8-75: IPH4502-101 Phase 1 (NCT06781983) Study - Initiation & Completion Year
Figure 8-76: 9MW2821-2021-CP102 Phase 1 (NCT05216965) Study - Initiation & Completion Year
Figure 9-1: Proprietary ADC Technology - Seagen
Figure 9-2: ALE.P02 & ALE.P03 - Alentis Therapeutics
Figure 9-3: TRAAC - Tallac Therapeutics
Figure 9-4: ATAC - Heidelberg Pharma
Figure 9-5: Tub-tag(R) & P5 - Tubulis
Figure 10-1: Mylotarg - FDA Approval, Withdrawal & Re-Approval Year
Figure 10-2: Mylotarg - Approval Year by Region
Figure 10-3: Mylotarg - Cost of 4.5 mg Supply in US (US$), July'2025
Figure 10-4: Adcetris - Approval Year by Region
Figure 10-5: US - Adcetris FDA Approval Year by Indication
Figure 10-6: Japan - Adcetris PMDA Approval Year by Indication
Figure 10-7: US - Adcetris Orphan Drug Designation Approval Year by Indication
Figure 10-8: Adcetris - Patent Expiration by Region
Figure 10-9: Adcetris - Cost of 50 mg Supply in US (US$), July'2025
Figure 10-10: US - Kadcyla FDA Approval Year by Indication
Figure 10-11: Kadcyla - Approval Year by Region
Figure 10-12: US - Kadcyla FDA Approval & Patent Expiration Year
Figure 10-13: Kadcyla - Cost of Supply in US & Europe (US$), July'2025
Figure 10-14: Kadcyla - Recommended Dose after 1st & 2nd Dose Reduction (mg/kg)
Figure 10-15: Besponsa - Approval Year by Region
Figure 10-16: Besponsa - Cost of 0.9 mg Supply in US & 1 mg Supply in Europe, July'2025
Figure 10-17: Lumoxiti - Orphan Designation Years
Figure 10-18: Lumoxiti - Patent Expiry Years
Figure 10-19: Lumoxiti - Cost of 1 mg Supply in US (US$), July'2025
Figure 10-20: Lumoxiti - Cost of 1 mg Supply in US & Europe (US$), July'2025
Figure 10-21: Polivy - Approval Year by Region
Figure 10-22: Polivy - Orphan Drug Designation Approval Year by Region
Figure 10-23: US - Polivy Orphan Drug Designation Approval & Exclusivity Year
Figure 10-24: Polivy - Cost of Supply in US & Europe (US$), July'2025
Figure 10-25: Padcev - Approval Year by Region
Figure 10-26: US - Padcev FDA Approval & Patent Expiration Year
Figure 10-27: Padcev - Cost of Supply In US & Europe (US$), July'2025
Figure 10-28: Enhertu - Approval Year by Region
Figure 10-29: US - Polivy FDA Approval Year by Indication
Figure 10-30: Enhertu - FDA Orphan Drug Designation & Exclusivity Expiration Year
Figure 10-31: Enhertu - Cost of 100 mg Supply In US & Europe (US$), July'2025
Figure 10-32: US - Trodelvy FDA Approval by Indication
Figure 10-33: Trodelvy - Approval Year by Region
Figure 10-34: Trodelvy - Patent Expiration by Region
Figure 10-35: Trodelvy - Cost of Supply In US & Europe (US$), July'2025
Figure 10-36: Blenrep - FDA & EMA Orphan Drug Designations
Figure 10-37: Blenrep - FDA & EMA Approval
Figure 10-38: Zynlonta - FDA & EMA Approval Years
Figure 10-39: Zynlonta - FDA & EMA Orphan Drug Designation Years
Figure 10-40: Zynlonta - Cost of 10 mg Supply In US & Europe (US$), July'2025
Figure 10-41: Tivdak - Cost of 40 mg Supply Europe (US$), July'2025
Figure 10-42: Ujvira - Cost of 100 mg & 160 mg Supply in India (US$), July'2025
Figure 10-43: Akalux - Sakigake Designation & PMDA Approval Year
Figure 10-44: Aidixi - China Approval Year & FDA Breakthrough Therapy Designation Year
Figure 10-45: Datroway - Cost of 100 mg Supply In US & Europe (US$), July'2025
Figure 11-1: Adcetris - Global Annual Sales (US$ Million), 2020-2025
Figure 11-2: Adcetris - Global Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 11-3: Adcetris - Global Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-4: Padcev - Global Annual Sales (US$ Million), 2020-2025
Figure 11-5: Padcev - Global Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 11-6: Padcev - Global Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-7: Tivdak - Global Annual Sales (US$ Million), 2021-2025
Figure 11-8: Tivdak - Global Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 11-9: Tivdak - Global Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-10: Polivy - Global Sales Values (US$ Million), 2020-2025
Figure 11-11: Polivy - Global Quarterly Sales Values (US$ Million), Q1 & Q2'2025
Figure 11-12: Polivy - Global Sales By Region (%), H1'2025
Figure 11-13: Polivy - Global Quarterly Sales Values (US$ Million), Q1-Q4'2024
Figure 11-14: Polivy - Global Sales By Region (US$ Million), 2024
Figure 11-15: Polivy - Global Sales By Region (%), 2024
Figure 11-16: Polivy - US Annual Sales Values (US$ Million), 2020-2025
Figure 11-17: Polivy - US Quarterly Sales Values (US$ Million), Q1 & Q2'2025
Figure 11-18: Polivy - US Quarterly Sales Values (US$ Million), Q1-Q4'2024
Figure 11-19: Polivy - Europe Annual Sales Values (US$ Million), 2020-2025
Figure 11-20: Polivy - Europe Quarterly Sales Values (US$ Million), Q1 & Q2'2025
Figure 11-21: Polivy - Europe Quarterly Sales Values (US$ Million), Q1-Q4'2024
Figure 11-22: Polivy - Japan Annual Sales Values (US$ Million), 2020-2025
Figure 11-23: Polivy - Japan Quarterly Sales Values (US$ Million), Q1 & Q2'2025
Figure 11-24: Polivy - Japan Quarterly Sales Values (US$ Million), Q1-Q4'2024
Figure 11-25: Polivy - ROW Annual Sales Values (US$ Million), 2020-2025
Figure 11-26: Polivy - ROW Quarterly Sales Values (US$ Million), Q1 & Q2'2025
Figure 11-27: Polivy - ROW Quarterly Sales Values (US$ Million), Q1-Q4'2024
Figure 11-28: Kadcyla - Global Sales Values (US$ Million), 2020-2025
Figure 11-29: Kadcyla - Global Quarterly Sales Values (US$ Million), Q1 & Q2'2025
Figure 11-30: Kadcyla - Global Sales By Region (%), H1'2025
Figure 11-31: Kadcyla - Global Quarterly Sales Values (US$ Million), Q1-Q4'2024
Figure 11-32: Kadcyla - Global Sales By Region (US$ Million), 2024
Figure 11-33: Kadcyla - Global Sales By Region (%), 2024
Figure 11-34: Kadcyla - US Annual Sales Values (US$ Million), 2020-2025
Figure 11-35: Kadcyla - US Quarterly Sales Values (US$ Million), Q1 & Q2'2025
Figure 11-36: Kadcyla - US Quarterly Sales Values (US$ Million), Q1-Q4'2024
Figure 11-37: Kadcyla - Europe Annual Sales Values (US$ Million), 2020-2025
Figure 11-38: Kadcyla - Europe Quarterly Sales Values (US$ Million), Q1'2025
Figure 11-39: Kadcyla - Europe Quarterly Sales Values (US$ Million), Q1-Q4'2024
Figure 11-40: Kadcyla - Japan Annual Sales Values (US$ Million), 2020-2025
Figure 11-41: Kadcyla - Japan Quarterly Sales Values (US$ Million), Q1 & Q2'2025
Figure 11-42: Kadcyla - Japan Quarterly Sales Values (US$ Million), Q1-Q4'2024
Figure 11-43: Kadcyla - ROW Annual Sales Values (US$ Million), 2020-2025
Figure 11-44: Kadcyla - ROW Quarterly Sales Values (US$ Million), Q1 & Q2'2025
Figure 11-45: Kadcyla - ROW Quarterly Sales Values (US$ Million), Q1-Q4'2024
Figure 11-46: Besponsa - Global Annual Sales (US$ Million), 2020-2023
Figure 11-47: Besponsa - Global Sales by Region (US$ Million), 2023
Figure 11-48: Besponsa - Quarterly Sales by Region (%), Q1-Q4'2024
Figure 11-49: Besponsa - Global Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-50: Besponsa - US Annual Sales (US$ Million), 2020-2023
Figure 11-51: Besponsa - Europe Quarterly Sales (US$ Million), 2022
Figure 11-52: Besponsa - ROW Quarterly Sales (US$ Million), 2022
Figure 11-53: Enhertu - Global Annual Sales (US$ Million), 2020-2025
Figure 11-54: Enhertu - Global Quarterly Sales Values (US$ Million), Q1 & Q2'2025
Figure 11-55: Enhertu - Global Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-56: Trodelvy - Global Annual Sales (US$ Million), 2020-2025
Figure 11-57: Trodelvy - Global Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 11-58: Trodelvy - Annual Sales By Region (US$ Million), 2025
Figure 11-59: Trodelvy - Annual Sales By Region (%), 2025
Figure 11-60: Trodelvy - Global Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-61: Trodelvy - Annual Sales By Region (US$ Million), 2024
Figure 11-62: Trodelvy - Annual Sales By Region (%), 2024
Figure 11-63: Trodelvy - US Annual Sales (US$ Million), 2020-2025
Figure 11-64: Trodelvy - US Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 11-65: Trodelvy - US Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-66: Trodelvy - Europe Annual Sales (US$ Million), 2020-2025
Figure 11-67: Trodelvy - Europe Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 11-68: Trodelvy - Europe Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-69: Trodelvy - ROW Annual Sales (US$ Million), 2022-2025
Figure 11-70: Trodelvy - ROW Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 11-71: Trodelvy - ROW Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-72: Zynlonta - Global Annual Sales (US$ Million), 2021-2025
Figure 11-73: Zynlonta - Global Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 11-74: Zynlonta - Global Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-75: Elahere - Global Annual Sales (US$ Million), 2022-2025
Figure 11-76: Elahere - Global Quarterly Sales (US$ Million), Q1-Q2'2025
Figure 11-77: Elahere - Global Quarterly Sales by Region (US$ Million), H2'2025
Figure 11-78: Elahere - Global Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-79: Blenrep - Global Annual Sales (US$ Million), 2020-2025
Figure 11-80: Blenrep - Europe Quarterly Sales Value (US$ Million), Q1-Q4'2024
Figure 11-81: Datroway - Global Annual Sales (US$ Million), 2025
Figure 12-1: Global - Cancer Antibody Drug Conjugate In Clinical Trials By Phase, 2025 Till 2031
Figure 14-1: Antibody Drug Conjugate Combinations in Studies
Figure 14-2: Approved Antibody Drug Conjugate Combinations

List of Tables

Table 4-1: First Generation Antibody Drug Conjugates - Examples
Table 4-2: Second Generation Antibody Drug Conjugates - Examples
Table 4-3: Third Generation Antibody Drug Conjugates - Examples
Table 4-4: Fourth Generation Antibody Drug Conjugates - Examples
Table 5-1: Approved Antibody Drug Conjugates, July'2025
Table 6-1: Cancer Antibody Drug Conjugates - Recent Collaborations
Table 6-2: Cancer Antibody Drug Conjugates - Companies Securing Funding for Clinical Development
Table 6-3: Cancer Antibody Drug Conjugates - Recent Regulatory Designations
Table 6-4: Cancer Antibody Drug Conjugates - Recent IND Clearances
Table 7-1: US - Approved Cancer Antibody Drug Conjugates, May'2025
Table 7-2: China - Approved Antibody Drug Conjugates, July'2025
Table 7-3: EU - Approved Cancer Antibody Drug Conjugates, July'2025
Table 7-4: Australia - Approved Cancer Antibody Drug Conjugates, July'2025
Table 7-5: UK - Approved Antibody Drug Conjugates, July'2025
Table 7-6: Canada - Approved Cancer Antibody Drug Conjugates, July'2025
Table 7-7: Japan - Approved Cancer Antibody Drug Conjugates, July'2025
Table 8-1: Lung Cancer - Approved Antibody Drug Conjugates, July'2025
Table 8-2: Breast Cancer - Approved Antibody Drug Conjugates, July'2025
Table 8-3: Leukemia - Approved Antibody Drug Conjugates, July'2025
Table 8-4: Ovarian Cancer - Approved Antibody Drug Conjugate
Table 8-5: Gastrointestinal Cancer - Approved Antibody Drug Conjugates
Table 8-6: Lymphoma - Approved Antibody Drug Conjugates
Table 8-7: Urogenital Cancer - Approved Antibody Drug Conjugates
Table 8-8: Cervical Cancer - Approved Antibody Drug Conjugates
Table 8-9: Head & Neck Cancer - Approved Antibody Drug Conjugates
Table 10-1: Adcetris - Recommended Dosage
Table 10-2: Datroway - Premedication and Concomitant Medications
Table 10-3: Datroway - Recommended Dosage Reductions for Adverse Reactions
Table 10-4: Emrelis: Recommended Dose Reductions
Table 14-1: Antibody Drug Conjugate Combinations - Ongoing Clinical Trials

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

DNA 片段市場按類型、產品類型、技術、應用和最終用戶分類—全球預測，2025-2030 年

雙特異性抗體藥物複合體的全球市場:臨床試驗，開發平台，競爭情形和市場機會(2025年)

Fc和糖基工程抗體市場：產業趨勢及全球預測 - 依修飾類型、治療類型、治療領域、給藥途徑和重點地區

雙特異性抗體市場，按藥物類型、按適應症、按配銷通路、按國家和地區 - 2025 年至 2032 年全球行業分析、市場規模、市場佔有率和預測

哺乳動物多株抗體IgG 抗體市場報告（按類型、產品、應用、最終用途和地區）2025 年至 2033 年

多特異性抗體的全球市場:藥物銷售額，用量，價格，臨床試驗趨勢(2030年)

抗體相關共同研究及授權契約:2019年～2025年

雙特異性抗體市場（按作用機制、治療領域和最終用戶分類）—2025-2030 年全球預測

中和抗體市場：按抗體類型、目標病毒、應用、最終用戶、銷售管道和地區分類

雙特異性抗體市場:各治療領域，各作用機制，標的抗原，抗體不同格式，各主要地區，各主要企業:2035年前的產業趨勢與全球預測

▼

FAQ

癌症抗體藥物複合體的全球市場:市場機會，專利，價格，已核准藥物銷售和臨床試驗趨勢(2031年)

Global Cancer Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales & Clinical Trials Insight 2031

目錄

第1章調查手法

第2章抗體藥物複合體的簡介

第3章癌症標靶治療的抗體藥物複合體

第4章抗體藥物複合體的世代

第5章就品牌名，公司名，各適應症裡來看市售核准抗體藥物複合體

第6章全球癌症抗體藥物複合體市場展望

第7章全球癌症抗體藥物複合體的調查與市場趨勢(各地區)

第8章全球癌症抗體藥物複合體市場趨勢與各適應症的開發

第9章各企業癌症抗體藥物複合體開發平台

第10章已核准癌症抗體藥物偶聯物 - 專利、劑量與定價分析

第11章已通過核准癌症抗體藥物複合體:2020年～2025年的銷售趨勢

第12章企業，國家，適應症，各相的世界癌症抗體藥物複合體臨床試驗的洞察

第13章市售被做的癌症抗體藥物複合體的臨床試驗:企業，國家，適應症，各相

第14章癌症抗體藥物複合體的聯合治療

第15章全球癌症抗體藥物複合體市場概要

第16章競爭情形